Literature DB >> 378485

Serum-migration inhibitory activity in patients with sarcoidosis.

T Yoshida, L E Siltzbach, N Masih, S Cohen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 378485     DOI: 10.1016/0090-1229(79)90018-7

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


× No keyword cloud information.
  6 in total

1.  Relationship between serum levels of macrophage migration inhibitory factor and the activity of antineutrophil cytoplasmic antibody-associated vasculitides.

Authors:  Heidemarie Becker; Christian Maaser; Eva Mickholz; Anke Dyong; Wolfram Domschke; Markus Gaubitz
Journal:  Clin Rheumatol       Date:  2006-01-04       Impact factor: 2.980

2.  Cellular immunity during follow-up of patients with sarcoidosis of varying duration.

Authors:  O Selroos; B Nikinmaa; E Koivunen; H Riska; H Tiitinen; T Weber
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

3.  Rosette-increasing factor (RIF) generated in vivo following PHA skin test.

Authors:  M Kubota; H Mikawa
Journal:  Clin Exp Immunol       Date:  1981-05       Impact factor: 4.330

4.  Circulating monocyte migration inhibitory factor in serum of Graves' ophthalmopathy patients: a parameter for disease activity?

Authors:  R van der Gaag; L Broersma; M P Mourits; L Koornneef; W M Wiersinga; M P Prummel; A Berghout
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

5.  Serum angiotensin-converting enzyme in malignant lymphomas, leukaemia and multiple myeloma.

Authors:  F K Rømer; K Emmertsen
Journal:  Br J Cancer       Date:  1980-08       Impact factor: 7.640

6.  Desensitization of delayed-type hypersensitivity in mice: suppressive environment.

Authors:  T Katsura; K Kobayashi; M Hosaka; S Sugihara; T Kasama; K Kasahara; S Cohen; T Yoshida
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.